![]() ![]() Next set of articles in this Journal for ImmunoTherapy of Cancer special review series on liquid biopsies will be coming soon focusing on cancer screening by cfDNA whole genome sequencing and methylation approaches! Lovly, MD, PhD and Aakash Desai, MD, MPH that masterfully addresses critical steps towards the clinical implementation of liquid biopsies and #ctDNA MRD. Here's the newest #liquidbiopsy expert-opinion article in the Society for Immunotherapy of Cancer (SITC) Journal for ImmunoTherapy of Cancer:Īadel Chaudhuri, MD PhD, Bruna Pellini and colleagues bring us up-to-speed with state-of-the-art #ctDNA #technologies and discuss the value, challenges, opportunities & emerging technologies for ctDNA minimal residual disease detection.Īlso see accompanying viewpoint by Christine M. The Democratization of Hematology-Oncology Medical Education during the COVID-19 Pandemic With gratitude for co-authors Arthi Sridhar Natasha Dhawan Andrea Anampa-Guzmán Eric Singhi and Ana Velazquez Mananaįor those interested in other post-pandemic-related changes discussed in this piece, please watch our #OncDataAdvisor i3 Health interview here: American Society of Clinical Oncology (ASCO) American Society of Hematology ASTCT OncoAlert OncoDaily We focus more on #DEI as a means of greater #inclusivity but also to decrease healthcare-related disparities #GME recruitment is mostly virtual now, with benefits including decreasedĬosts and less travel but cons including less familiarity with institutions, communities, and populationsĦ. We work differently now as our previous partner piece led by Rahul Banerjee detailedĥ. In fact, this piece originated from an online invitation from Nicole Kuderer Gary Lyman and Aakash Desai, MD, MPH -thank you!Ĥ. We use much more #MedTech, such as podcasts (too many to name, but consider following and We connect more on #MedTwitter. #MedEd philosophy changed in our fellowship and other #GME training structuresĢ. Why is this topic important for other #Heme #MedOnc trainees in #GME?ġ. Our article highlighting the democratization of #MedEd as a silver lining of the #COVID19 pandemic is fresh off the press: Rohit Gosain, MD Ishwaria Subbiah, MD, MS Ana Velazquez Manana □ Amivantamab+lazertinib could be a chemo-free option for EGFR-mutated advanced NSCLC post-osimertinib, especially for MET+ pts by IHC.Īndrea Anampa-Guzmán Devika Das MD, MSHQS Martina Murphy Rahul Gosain, M.D. ➡️ No predictive biomarkers identified via ctDNA NGS□. ➡️101 evaluable patients, IHC-based MET expression found predictive for response□. Abs9042 #LCSM #CHRYSALIS2: Amivantamab+lazertinib in post-osimertinib, chemo-naïve EGFR-mutated advanced NSCLC. □ This approach revealed heterogeneity in real-world survival outcomesĦ. □ In in-silico trials, survival benefits varied across risk groups and were generally lower compared to RCTs, especially among high-risk patients. ➡️Best-performing gradient boosted model outperformed Lung Cancer Prognostic Index (AUC 0.784 vs 0.688). □ New study leverages ML to simulate two pivotal trials in 1L aNSCLC with real-world data from 61,339 patients. □ Combined Deep-IO+PD-L1 score improved AUROC to 0.82, 32% increase in specificity compared to PD-L1 alone. ![]() ➡️ Outperformed both PD-L1 expression and TMB in predictive power (AUROC=0.75). □️ Training with 85218 tiles from 446 patients, the model achieved an accuracy of 0.72 in distinguishing responders from non-responders. □ Novel AI tool, Deep-IO, shows promise in predicting response to ICIs in NSCLC using H&E images. ➡️ Underscores the potential of tepotinib in clinical practice. □ Long-term outcomes of #VISION trial highlight robust and durable clinical activity of tepotinib in METex14 skipping NSCLC, particularly in 1L tissue+ patients. □ Findings underscore the need for wider accessibility of NGS testing and education. ➡️ OS benefit associated with earlier targeted therapy initiation □. ➡️ Median OS longest in patients with upfront NGS vs. ➡️ Percentage of patients with upfront NGS increased from 29% in 2019 to 66% in 2022 □. □ Largest study yet showing upfront NGS testing leads to better OS compared to upfront non-NGS, later NGS, or no-NGS in aNSCLC □. □ Results inform future use of early ctDNA response assessment ![]() ➡️ Lack of treatment-induced decrease in ctDNA may predict inferior OS from cemi as early as 3 weeks into therapy □. 29 months (MR) and 8 months (no decrease) □. ➡️ cemi patients with complete ctDNA clearance showed longest survival, median OS not reached vs. ![]() ➡️ ctDNA at W9 associated with clinical response to cemi, but not chemo □. □ EMPOWER-Lung 1: Correlating ctDNA levels with outcomes in 1L aNSCLC treated with cemi or chemo □. □□ some #LCSM #lungcancer studies of interest at American Society of Clinical Oncology (ASCO) #asco23 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |